Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140846 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL79536 | 0.88 | DAO (0.33) | — | |
| O-Tolylamine SCHEMBL9229915 | 0.84 | MAP2 (0.33) | — | |
| SCHEMBL79535 | 0.77 | DAO (0.32) | — | |
| Tetrazole SCHEMBL5041698 | 0.77 | — | — | |
| Tetrazole SCHEMBL3922918 | 0.77 | — | — | |
| Tetrazole SCHEMBL5041695 | 0.77 | — | — | |
| Tetrazole SCHEMBL6400674 | 0.76 | — | — | |
| SCHEMBL3739490 | 0.76 | HTR2A (0.36) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL1474652 | 0.76 | HTR2A (0.36) | ALDH1A1MAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007140525-A1 | A METHOD OF TREATMENT AND PROPHYLAXIS OF EVENTS, CONDITIONS AND DISEASES OF THE SYSTEMIC VASCULATURE AN IMMUNE FUNCTION TO DECREASE CARDIOVASCULAR RISK AND PATHOGENIC INFECTION | HOENIG MICHEL (AU) | 2007-12-13 | — | — | WO | disclosed |
| US-6932968-B1 | Erythropoietin (EPO) peptides and antibodies directed against these | DADE BEHRING MARBURG GMBH (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20030180324-A1 | Lentivirus from the group of immunodeficiency viruses of drill monkeys (Mandrillus leucophaeus) and their use | GUERTLER LUTZ GERHARD (DE) | 2003-09-25 | — | — | US | disclosed |
| US-6566513-B1 | Nucleotide sequences coding polypeptide for use as viricide | DADE BEHRING MARBURG GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| US-5712370-A | Erythropoietin (EPO) peptides and antibodies directed against these | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | disclosed |
| US-5106954-A | ERYTHROPOIETIN (EPO) PEPTIDES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1992-04-21 | — | — | US | disclosed |